<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20231214050934&amp;v=2.18.0&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20231214050934&amp;v=2.18.0&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Thu, 14 Dec 2023 10:09:38 +0000</lastbuilddate>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Global Burden of Cardiovascular Diseases and Risks, 1990-2022</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38092509/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 19;82(25):2350-2473. doi: 10.1016/j.jacc.2023.11.007.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38092509/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38092509</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.007>10.1016/j.jacc.2023.11.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38092509</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>George A Mensah</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:creator>Christopher J L Murray</dc:creator>
<dc:creator>Gregory A Roth</dc:creator>
<dc:creator>Global Burden of Cardiovascular Diseases and Risks Collaborators</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Global Burden of Cardiovascular Diseases and Risks, 1990-2022</dc:title>
<dc:identifier>pmid:38092509</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.007</dc:identifier>
</item>
<item>
<title>A Heart-Healthy and Stroke-Free World: Using Data to Inform Global Action</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38092508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 19;82(25):2343-2349. doi: 10.1016/j.jacc.2023.11.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38092508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38092508</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.11.003>10.1016/j.jacc.2023.11.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38092508</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>George A Mensah</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:creator>Gregory A Roth</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Heart-Healthy and Stroke-Free World: Using Data to Inform Global Action</dc:title>
<dc:identifier>pmid:38092508</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.11.003</dc:identifier>
</item>
<item>
<title>Spatiotemporal transcriptome atlas reveals the regional specification of the developing human brain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38091994/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>Different functional regions of brain are fundamental for basic neurophysiological activities. However, the regional specification remains largely unexplored during human brain development. Here, by combining spatial transcriptomics (scStereo-seq) and scRNA-seq, we built a spatiotemporal developmental atlas of multiple human brain regions from 6-23 gestational weeks (GWs). We discovered that, around GW8, radial glia (RG) cells have displayed regional heterogeneity and specific spatial...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 2:S0092-8674(23)01233-3. doi: 10.1016/j.cell.2023.11.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Different functional regions of brain are fundamental for basic neurophysiological activities. However, the regional specification remains largely unexplored during human brain development. Here, by combining spatial transcriptomics (scStereo-seq) and scRNA-seq, we built a spatiotemporal developmental atlas of multiple human brain regions from 6-23 gestational weeks (GWs). We discovered that, around GW8, radial glia (RG) cells have displayed regional heterogeneity and specific spatial distribution. Interestingly, we found that the regional heterogeneity of RG subtypes contributed to the subsequent neuronal specification. Specifically, two diencephalon-specific subtypes gave rise to glutamatergic and GABAergic neurons, whereas subtypes in ventral midbrain were associated with the dopaminergic neurons. Similar GABAergic neuronal subtypes were shared between neocortex and diencephalon. Additionally, we revealed that cell-cell interactions between oligodendrocyte precursor cells and GABAergic neurons influenced and promoted neuronal development coupled with regional specification. Altogether, this study provides comprehensive insights into the regional specification in the developing human brain.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38091994/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38091994</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.016>10.1016/j.cell.2023.11.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38091994</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Yanxin Li</dc:creator>
<dc:creator>Zhongqiu Li</dc:creator>
<dc:creator>Changliang Wang</dc:creator>
<dc:creator>Min Yang</dc:creator>
<dc:creator>Ziqing He</dc:creator>
<dc:creator>Feiyang Wang</dc:creator>
<dc:creator>Yuehong Zhang</dc:creator>
<dc:creator>Rong Li</dc:creator>
<dc:creator>Yunxia Gong</dc:creator>
<dc:creator>Binhong Wang</dc:creator>
<dc:creator>Baoguang Fan</dc:creator>
<dc:creator>Chunyue Wang</dc:creator>
<dc:creator>Lei Chen</dc:creator>
<dc:creator>Hong Li</dc:creator>
<dc:creator>Peifu Shi</dc:creator>
<dc:creator>Nana Wang</dc:creator>
<dc:creator>Zhifeng Wei</dc:creator>
<dc:creator>Yan-Ling Wang</dc:creator>
<dc:creator>Lei Jin</dc:creator>
<dc:creator>Peng Du</dc:creator>
<dc:creator>Ji Dong</dc:creator>
<dc:creator>Jianwei Jiao</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Spatiotemporal transcriptome atlas reveals the regional specification of the developing human brain</dc:title>
<dc:identifier>pmid:38091994</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.016</dc:identifier>
</item>
<item>
<title>Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38091993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>Multiple sclerosis (MS) is a demyelinating disease of the CNS. Epstein-Barr virus (EBV) contributes to the MS pathogenesis because high levels of EBV EBNA(386-405)-specific antibodies cross react with the CNS-derived GlialCAM(370-389). However, it is unclear why only some individuals with such high autoreactive antibody titers develop MS. Here, we show that autoreactive cells are eliminated by distinct immune responses, which are determined by genetic variations of the host, as well as of the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 3:S0092-8674(23)01232-1. doi: 10.1016/j.cell.2023.11.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Multiple sclerosis (MS) is a demyelinating disease of the CNS. Epstein-Barr virus (EBV) contributes to the MS pathogenesis because high levels of EBV EBNA<sub>386-405</sub>-specific antibodies cross react with the CNS-derived GlialCAM<sub>370-389</sub>. However, it is unclear why only some individuals with such high autoreactive antibody titers develop MS. Here, we show that autoreactive cells are eliminated by distinct immune responses, which are determined by genetic variations of the host, as well as of the infecting EBV and human cytomegalovirus (HCMV). We demonstrate that potent cytotoxic NKG2C<sup>+</sup> and NKG2D<sup>+</sup> natural killer (NK) cells and distinct EBV-specific T cell responses kill autoreactive GlialCAM<sub>370-389</sub>-specific cells. Furthermore, immune evasion of these autoreactive cells was induced by EBV-variant-specific upregulation of the immunomodulatory HLA-E. These defined virus and host genetic pre-dispositions are associated with an up to 260-fold increased risk of MS. Our findings thus allow the early identification of patients at risk for MS and suggest additional therapeutic options against MS.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38091993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38091993</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.015>10.1016/j.cell.2023.11.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38091993</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Hannes Vietzen</dc:creator>
<dc:creator>Sarah M Berger</dc:creator>
<dc:creator>Laura M Kühner</dc:creator>
<dc:creator>Philippe L Furlano</dc:creator>
<dc:creator>Gabriel Bsteh</dc:creator>
<dc:creator>Thomas Berger</dc:creator>
<dc:creator>Paulus Rommer</dc:creator>
<dc:creator>Elisabeth Puchhammer-Stöckl</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis</dc:title>
<dc:identifier>pmid:38091993</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.015</dc:identifier>
</item>
<item>
<title>Correction to: HFrEF phenotyping in real life</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38092693/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 13:ehad839. doi: 10.1093/eurheartj/ehad839. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38092693/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38092693</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad839>10.1093/eurheartj/ehad839</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38092693</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:date>2023-12-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: HFrEF phenotyping in real life</dc:title>
<dc:identifier>pmid:38092693</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad839</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38091001/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 1;8(12):1106. doi: 10.1001/jamacardio.2022.3464.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38091001/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38091001</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2022.3464>10.1001/jamacardio.2022.3464</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38091001</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:date>2023-12-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:38091001</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2022.3464</dc:identifier>
</item>
<item>
<title>Mineralocorticoid Receptor Antagonism by Eplerenone and Arterial Inflammation in HIV: The MIRABELLA HIV Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38090987/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>CONCLUSION AND RELEVANCE: In this small randomized clinical trial, eplerenone was associated with reduction in arterial inflammation among well-treated PWH without known CVD. In addition, reductions in arterial inflammation as measured by 18F-FDG PET/CT were related to improvements in stress myocardial perfusion. Further larger studies should explore whether eplerenone is a potential treatment strategy for inflammatory-mediated CVD in PWH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Dec 13. doi: 10.1001/jamacardio.2023.4578. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The risk for atherosclerotic disease is increased 1.5- to 2.0-fold among persons with HIV (PWH). Increased activation of the renin-angiotensin-aldosterone system may contribute to increased arterial inflammation in this population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the effects of eplerenone on arterial inflammation among well-treated PWH without known cardiovascular disease (CVD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Well-treated PWH who participated in the double-blinded, placebo-controlled, Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV (MIRACLE HIV) study between February 2017 and March 2022 assessing the effects of eplerenone on myocardial perfusion were invited to participate in the Mineralocorticoid Receptor Antagonism By Eplerenone to Lower Arterial Inflammation in HIV (MIRABELLA) substudy if there was no current statin use. Participants were enrolled in the MIRABELLA study and underwent additional 18F-fludeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) imaging of the aorta and carotid arteries to assess arterial inflammation over 12 months of treatment with eplerenone vs placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Eplerenone, 50 mg, twice a day vs identical placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was change in target to background ratio (TBR), a measure of arterial wall inflammation, in the index vessel after 12 months of treatment. The index vessel was defined as the vessel (aorta, left carotid artery, or right carotid artery) with the highest TBR at baseline in each participant.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 26 participants (mean [SD] age, 54 [7] years; 18 male [69%]) were enrolled in the study. Treatment groups (eplerenone, 13 vs placebo, 13) were of similar age, sex, and body mass index. Eplerenone was associated with a reduction in TBR of the primary end point, the index vessel (eplerenone vs placebo: model treatment effect, -0.31; 95% CI, -0.50 to -0.11; P = .006; percentage change, -12.4% [IQR, -21.9% to -2.6%] vs 5.1% [IQR, -1.6% to 11.0%]; P = .003). We further observed a significant reduction of the TBR of the most diseased segment (MDS) of the index vessel (eplerenone vs placebo: -19.1% [IQR, -27.0% to -11.9%] vs 6.8% [IQR, -9.1% to 12.1%]; P = .007). A similar result was seen assessing the index vessel of the carotids (eplerenone vs placebo: -10.0% [IQR, -21.8% to 3.6%] vs 9.7% [IQR, -9.8% to 15.9%]; P = .046). Reduction in the TBR of MDS of the index vessel on 18F-FDG PET/CT correlated with improvement in the stress myocardial blood flow on cardiac magnetic resonance imaging (Spearman ρ = -0.67; P = .01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: In this small randomized clinical trial, eplerenone was associated with reduction in arterial inflammation among well-treated PWH without known CVD. In addition, reductions in arterial inflammation as measured by 18F-FDG PET/CT were related to improvements in stress myocardial perfusion. Further larger studies should explore whether eplerenone is a potential treatment strategy for inflammatory-mediated CVD in PWH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02740179.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38090987/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38090987</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.4578>10.1001/jamacardio.2023.4578</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38090987</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Suman Srinivasa</dc:creator>
<dc:creator>Shady Abohashem</dc:creator>
<dc:creator>Allie R Walpert</dc:creator>
<dc:creator>Carolyn N Dunderdale</dc:creator>
<dc:creator>Sanjna Iyengar</dc:creator>
<dc:creator>Grace Shen</dc:creator>
<dc:creator>Michael Jerosch-Herold</dc:creator>
<dc:creator>Christopher R deFilippi</dc:creator>
<dc:creator>Gregory K Robbins</dc:creator>
<dc:creator>Hang Lee</dc:creator>
<dc:creator>Raymond Y Kwong</dc:creator>
<dc:creator>Gail K Adler</dc:creator>
<dc:creator>Ahmed Tawakol</dc:creator>
<dc:creator>Steven K Grinspoon</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Mineralocorticoid Receptor Antagonism by Eplerenone and Arterial Inflammation in HIV: The MIRABELLA HIV Study</dc:title>
<dc:identifier>pmid:38090987</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.4578</dc:identifier>
</item>
<item>
<title>ChatGPT hallucinating: can it get any more humanlike?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38088452/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 13:ehad766. doi: 10.1093/eurheartj/ehad766. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38088452/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38088452</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad766>10.1093/eurheartj/ehad766</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38088452</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Konstantinos C Siontis</dc:creator>
<dc:creator>Zachi I Attia</dc:creator>
<dc:creator>Samuel J Asirvatham</dc:creator>
<dc:creator>Paul A Friedman</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>ChatGPT hallucinating: can it get any more humanlike?</dc:title>
<dc:identifier>pmid:38088452</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad766</dc:identifier>
</item>
<item>
<title>Residual leaks following percutaneous left atrial appendage occlusion and outcomes: a meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38088437/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>CONCLUSIONS: Peri-device leak detected by TEE was associated with adverse events, primarily thromboembolism. Residual leaks detected by CT were more frequent but lacked prognostic significance.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 13:ehad828. doi: 10.1093/eurheartj/ehad828. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Residual leaks are not infrequent after left atrial appendage occlusion. However, there is still uncertainty regarding their prognostic implications. The aim of this study is to evaluate the impact of residual leaks after left atrial appendage occlusion.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A literature search was conducted until 19 February 2023. Residual leaks comprised peri-device leaks (PDLs) on transoesophageal echocardiography (TEE) or computed tomography (CT), as well as left atrial appendage patency on CT. Random-effects meta-analyses were performed to assess the clinical impact of residual leaks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall 48 eligible studies (44 non-randomized/observational and 4 randomized studies) including 61 666 patients with atrial fibrillation who underwent left atrial appendage occlusion were analysed. Peri-device leak by TEE was present in 26.1% of patients. Computed tomography-based left atrial appendage patency and PDL were present in 54.9% and 57.3% of patients, respectively. Transoesophageal echocardiography-based PDL (i.e. any reported PDL regardless of its size) was significantly associated with a higher risk of thromboembolism [pooled odds ratio (pOR) 2.04, 95% confidence interval (CI): 1.52-2.74], all-cause mortality (pOR 1.16, 95% CI: 1.08-1.24), and major bleeding (pOR 1.12, 95% CI: 1.03-1.22), compared with no reported PDL. A positive graded association between PDL size and risk of thromboembolism was noted across TEE cut-offs. For any PDL of >;0, >;1, >;3, and >;5 mm, the pORs for thromboembolism were 1.82 (95% CI: 1.35-2.47), 2.13 (95% CI: 1.04-4.35), 4.14 (95% CI: 2.07-8.27), and 4.44 (95% CI: 2.09-9.43), respectively, compared with either no PDL or PDL smaller than each cut-off. Neither left atrial appendage patency, nor PDL by CT was associated with thromboembolism (pOR 1.45 and 1.04, 95% CI: 0.84-2.50 and 0.52-2.07, respectively).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Peri-device leak detected by TEE was associated with adverse events, primarily thromboembolism. Residual leaks detected by CT were more frequent but lacked prognostic significance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38088437/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38088437</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad828>10.1093/eurheartj/ehad828</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38088437</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Athanasios Samaras</dc:creator>
<dc:creator>Andreas S Papazoglou</dc:creator>
<dc:creator>Charalampos Balomenakis</dc:creator>
<dc:creator>Alexandra Bekiaridou</dc:creator>
<dc:creator>Dimitrios V Moysidis</dc:creator>
<dc:creator>Vasiliki Patsiou</dc:creator>
<dc:creator>Antonios Orfanidis</dc:creator>
<dc:creator>George Giannakoulas</dc:creator>
<dc:creator>George Kassimis</dc:creator>
<dc:creator>Nikolaos Fragakis</dc:creator>
<dc:creator>Jacqueline Saw</dc:creator>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:creator>Mohamad Adnan Alkhouli</dc:creator>
<dc:creator>Apostolos Tzikas</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Residual leaks following percutaneous left atrial appendage occlusion and outcomes: a meta-analysis</dc:title>
<dc:identifier>pmid:38088437</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad828</dc:identifier>
</item>
<item>
<title>Visualizing the unseen: lights and shadows of imaging in the electrophysiology laboratory</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38088436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 13:ehad777. doi: 10.1093/eurheartj/ehad777. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38088436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38088436</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad777>10.1093/eurheartj/ehad777</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38088436</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Francesco De Sensi</dc:creator>
<dc:creator>Diego Penela</dc:creator>
<dc:creator>Ugo Limbruno</dc:creator>
<dc:creator>Antonio Berruezo</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Visualizing the unseen: lights and shadows of imaging in the electrophysiology laboratory</dc:title>
<dc:identifier>pmid:38088436</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad777</dc:identifier>
</item>
<item>
<title>Randomized controlled trials are not always the solution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38087934/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 13:ehad805. doi: 10.1093/eurheartj/ehad805. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38087934/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38087934</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad805>10.1093/eurheartj/ehad805</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38087934</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Sara Finocchietti</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Randomized controlled trials are not always the solution</dc:title>
<dc:identifier>pmid:38087934</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad805</dc:identifier>
</item>
<item>
<title>Intricacies of aortic risk assessment studies: not a simple matter</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38087929/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 13:ehad795. doi: 10.1093/eurheartj/ehad795. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38087929/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38087929</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad795>10.1093/eurheartj/ehad795</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38087929</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Mohammad A Zafar</dc:creator>
<dc:creator>Jinlin Wu</dc:creator>
<dc:creator>John A Elefteriades</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intricacies of aortic risk assessment studies: not a simple matter</dc:title>
<dc:identifier>pmid:38087929</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad795</dc:identifier>
</item>
<item>
<title>Randomized controlled trials remain underutilized</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38087906/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 13:ehad806. doi: 10.1093/eurheartj/ehad806. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38087906/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38087906</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad806>10.1093/eurheartj/ehad806</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38087906</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>George C M Siontis</dc:creator>
<dc:creator>André Frenk</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Randomized controlled trials remain underutilized</dc:title>
<dc:identifier>pmid:38087906</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad806</dc:identifier>
</item>
<item>
<title>Fate of the unoperated ascending thoracic aortic aneurysm-patient selection and the importance of the denominator</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38087827/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 13:ehad794. doi: 10.1093/eurheartj/ehad794. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38087827/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38087827</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad794>10.1093/eurheartj/ehad794</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38087827</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Matthew D Solomon</dc:creator>
<dc:creator>David H Liang</dc:creator>
<dc:creator>D Craig Miller</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fate of the unoperated ascending thoracic aortic aneurysm-patient selection and the importance of the denominator</dc:title>
<dc:identifier>pmid:38087827</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad794</dc:identifier>
</item>
<item>
<title>Alternatives to animal experimentation in cardiovascular research: human models of disease and biobanking</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38087812/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 13:ehad709. doi: 10.1093/eurheartj/ehad709. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38087812/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38087812</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad709>10.1093/eurheartj/ehad709</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38087812</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Inês Falcão-Pires</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Alternatives to animal experimentation in cardiovascular research: human models of disease and biobanking</dc:title>
<dc:identifier>pmid:38087812</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad709</dc:identifier>
</item>
<item>
<title>Transcatheter valvular interventions 2022: insights from the National Societies of Cardiology Journals of the European Society of Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38087771/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 13:ehad676. doi: 10.1093/eurheartj/ehad676. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38087771/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38087771</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad676>10.1093/eurheartj/ehad676</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38087771</guid>
<pubDate>Wed, 13 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Jean-Jacques Monsuez</dc:creator>
<dc:creator>Plamen Gatzov</dc:creator>
<dc:creator>Fernando Alfonso</dc:creator>
<dc:creator>Editors’ Network of the National Societies of Cardiology Journals, European Society of Cardiology</dc:creator>
<dc:date>2023-12-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transcatheter valvular interventions 2022: insights from the National Societies of Cardiology Journals of the European Society of Cardiology</dc:title>
<dc:identifier>pmid:38087771</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad676</dc:identifier>
</item>
<item>
<title>Correction to: 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38086544/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 13:ehad776. doi: 10.1093/eurheartj/ehad776. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38086544/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38086544</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad776>10.1093/eurheartj/ehad776</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38086544</guid>
<pubDate>Tue, 12 Dec 2023 06:00:00 -0500</pubDate>
<dc:date>2023-12-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM)</dc:title>
<dc:identifier>pmid:38086544</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad776</dc:identifier>
</item>
<item>
<title>APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38086389/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>A recent case report described an individual who was a homozygous carrier of the APOE3 Christchurch (APOE3ch) mutation and resistant to autosomal dominant Alzheimer's Disease (AD) caused by a PSEN1-E280A mutation. Whether APOE3ch contributed to the protective effect remains unclear. We generated a humanized APOE3ch knock-in mouse and crossed it to an amyloid-β (Aβ) plaque-depositing model. We injected AD-tau brain extract to investigate tau seeding and spreading in the presence or absence of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Dec 6:S0092-8674(23)01315-6. doi: 10.1016/j.cell.2023.11.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A recent case report described an individual who was a homozygous carrier of the APOE3 Christchurch (APOE3ch) mutation and resistant to autosomal dominant Alzheimer's Disease (AD) caused by a PSEN1-E280A mutation. Whether APOE3ch contributed to the protective effect remains unclear. We generated a humanized APOE3ch knock-in mouse and crossed it to an amyloid-β (Aβ) plaque-depositing model. We injected AD-tau brain extract to investigate tau seeding and spreading in the presence or absence of amyloid. Similar to the case report, APOE3ch expression resulted in peripheral dyslipidemia and a marked reduction in plaque-associated tau pathology. Additionally, we observed decreased amyloid response and enhanced microglial response around plaques. We also demonstrate increased myeloid cell phagocytosis and degradation of tau aggregates linked to weaker APOE3ch binding to heparin sulfate proteoglycans. APOE3ch influences the microglial response to Aβ plaques, which suppresses Aβ-induced tau seeding and spreading. The results reveal new possibilities to target Aβ-induced tauopathy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38086389/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38086389</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.11.029>10.1016/j.cell.2023.11.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38086389</guid>
<pubDate>Tue, 12 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Yun Chen</dc:creator>
<dc:creator>Sihui Song</dc:creator>
<dc:creator>Samira Parhizkar</dc:creator>
<dc:creator>Jennifer Lord</dc:creator>
<dc:creator>Yiyang Zhu</dc:creator>
<dc:creator>Michael R Strickland</dc:creator>
<dc:creator>Chanung Wang</dc:creator>
<dc:creator>Jiyu Park</dc:creator>
<dc:creator>G Travis Tabor</dc:creator>
<dc:creator>Hong Jiang</dc:creator>
<dc:creator>Kevin Li</dc:creator>
<dc:creator>Albert A Davis</dc:creator>
<dc:creator>Carla M Yuede</dc:creator>
<dc:creator>Marco Colonna</dc:creator>
<dc:creator>Jason D Ulrich</dc:creator>
<dc:creator>David M Holtzman</dc:creator>
<dc:date>2023-12-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread</dc:title>
<dc:identifier>pmid:38086389</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.11.029</dc:identifier>
</item>
<item>
<title>Myocardial infarction drives trained immunity of monocytes, accelerating atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38085922/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>CONCLUSIONS: The findings underscore the crucial role of monocyte trained immunity in accelerated atherosclerosis after MI, implying that SYK in blood classical monocytes may serve as a predictive factor for the progression of atherosclerosis in STEMI patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 12:ehad787. doi: 10.1093/eurheartj/ehad787. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Survivors of acute coronary syndromes face an elevated risk of recurrent atherosclerosis-related vascular events despite advanced medical treatments. The underlying causes remain unclear. This study aims to investigate whether myocardial infarction (MI)-induced trained immunity in monocytes could sustain proatherogenic traits and expedite atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Apolipoprotein-E deficient (ApoE-/-) mice and adoptive bone marrow transfer chimeric mice underwent MI or myocardial ischaemia-reperfusion (IR). A subsequent 12-week high-fat diet (HFD) regimen was implemented to elucidate the mechanism behind monocyte trained immunity. In addition, classical monocytes were analysed by flow cytometry in the blood of enrolled patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In MI and IR mice, blood monocytes and bone marrow-derived macrophages exhibited elevated spleen tyrosine kinase (SYK), lysine methyltransferase 5A (KMT5A), and CCHC-type zinc finger nucleic acid-binding protein (CNBP) expression upon exposure to a HFD or oxidized LDL (oxLDL) stimulation. MI-induced trained immunity was transmissible by transplantation of bone marrow to accelerate atherosclerosis in naive recipients. KMT5A specifically recruited monomethylation of Lys20 of histone H4 (H4K20me) to the gene body of SYK and synergistically transactivated SYK with CNBP. In vivo small interfering RNA (siRNA) inhibition of KMT5A or CNBP potentially slowed post-MI atherosclerosis. Sympathetic denervation with 6-hydroxydopamine reduced atherosclerosis and inflammation after MI. Classical monocytes from ST-elevation MI (STEMI) patients with advanced coronary lesions expressed higher SYK and KMT5A gene levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The findings underscore the crucial role of monocyte trained immunity in accelerated atherosclerosis after MI, implying that SYK in blood classical monocytes may serve as a predictive factor for the progression of atherosclerosis in STEMI patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38085922/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38085922</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad787>10.1093/eurheartj/ehad787</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38085922</guid>
<pubDate>Tue, 12 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Zheng Dong</dc:creator>
<dc:creator>Lei Hou</dc:creator>
<dc:creator>Wei Luo</dc:creator>
<dc:creator>Li-Hong Pan</dc:creator>
<dc:creator>Xiao Li</dc:creator>
<dc:creator>Hai-Peng Tan</dc:creator>
<dc:creator>Run-Da Wu</dc:creator>
<dc:creator>Hao Lu</dc:creator>
<dc:creator>Kang Yao</dc:creator>
<dc:creator>Man-Di Mu</dc:creator>
<dc:creator>Chen-Shan Gao</dc:creator>
<dc:creator>Xin-Yu Weng</dc:creator>
<dc:creator>Jun-Bo Ge</dc:creator>
<dc:date>2023-12-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Myocardial infarction drives trained immunity of monocytes, accelerating atherosclerosis</dc:title>
<dc:identifier>pmid:38085922</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad787</dc:identifier>
</item>
<item>
<title>The European Heart Journal's top contributing institutions: the Centre for Cardiovascular Science at the University of Edinburgh, Scotland</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38085601/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 12:ehad780. doi: 10.1093/eurheartj/ehad780. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38085601/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38085601</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad780>10.1093/eurheartj/ehad780</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38085601</guid>
<pubDate>Tue, 12 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2023-12-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The European Heart Journal's top contributing institutions: the Centre for Cardiovascular Science at the University of Edinburgh, Scotland</dc:title>
<dc:identifier>pmid:38085601</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad780</dc:identifier>
</item>
<item>
<title>Hepatocellular carcinoma in survivors after Fontan operation: a case-control study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38085593/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231214050934&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Dec 12:ehad788. doi: 10.1093/eurheartj/ehad788. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38085593/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231214050934&v=2.18.0">38085593</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad788>10.1093/eurheartj/ehad788</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38085593</guid>
<pubDate>Tue, 12 Dec 2023 06:00:00 -0500</pubDate>
<dc:creator>Yuli Y Kim</dc:creator>
<dc:creator>Gentian Lluri</dc:creator>
<dc:creator>Christiane Haeffele</dc:creator>
<dc:creator>Tami Daugherty</dc:creator>
<dc:creator>Richard A Krasuski</dc:creator>
<dc:creator>John D Serfas</dc:creator>
<dc:creator>R Andrew de Freitas</dc:creator>
<dc:creator>Avaliese Porlier</dc:creator>
<dc:creator>Adam M Lubert</dc:creator>
<dc:creator>Fred M Wu</dc:creator>
<dc:creator>Anne Marie Valente</dc:creator>
<dc:creator>Eric V Krieger</dc:creator>
<dc:creator>Jonathan Buber</dc:creator>
<dc:creator>Fred H Rodriguez</dc:creator>
<dc:creator>Scott Gaignard</dc:creator>
<dc:creator>Anita Saraf</dc:creator>
<dc:creator>Morgan Hindes</dc:creator>
<dc:creator>Michael G Earing</dc:creator>
<dc:creator>Matthew J Lewis</dc:creator>
<dc:creator>Marlon S Rosenbaum</dc:creator>
<dc:creator>Ali N Zaidi</dc:creator>
<dc:creator>Kali Hopkins</dc:creator>
<dc:creator>Elisa A Bradley</dc:creator>
<dc:creator>Ari M Cedars</dc:creator>
<dc:creator>Jong L Ko</dc:creator>
<dc:creator>Wayne J Franklin</dc:creator>
<dc:creator>Abby Frederickson</dc:creator>
<dc:creator>Salil Ginde</dc:creator>
<dc:creator>Jasmine Grewal</dc:creator>
<dc:creator>Annique Nyman</dc:creator>
<dc:creator>Jungwon Min</dc:creator>
<dc:creator>Charlotte Schluger</dc:creator>
<dc:creator>Elizabeth Rand</dc:creator>
<dc:creator>Benjamin E Rosenthal</dc:creator>
<dc:creator>Moira Hilscher</dc:creator>
<dc:creator>Jack Rychik</dc:creator>
<dc:creator>Maarouf A Hoteit</dc:creator>
<dc:date>2023-12-12</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hepatocellular carcinoma in survivors after Fontan operation: a case-control study</dc:title>
<dc:identifier>pmid:38085593</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad788</dc:identifier>
</item>





























</channel>
</rss>